Skip to content
TrialMatch
Sign up
Recruiting

Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The introduction of immune checkpoint inhibitors (ICIs) for the treatment of patients with stages IIB to IV cutaneous melanoma resulted in dramatic improvements in mortality rates for this common form of cancer. With this rapid shift in treatment, significant gaps in knowledge exist regarding the impact of ICIs on patients' symptom experiences. An in-depth characterization of inter-individual differences in patients' symptom experiences will fill this knowledge gap and assist with the early detection of ICI toxicity; guide symptom management; inform treatment decision making; and refine ICI-symptom instrument development. Furthermore, given the limited knowledge in this area, the identification of demographic, clinical, environmental, and molecular risk factors associated with a worse symptom experience is warranted. This is a longitudinal, prospective study evaluating the symptoms that immune checkpoint inhibitors may cause in patients with cutaneous melanoma.

Condition
Cutaneous Melanoma, Cutaneous Melanoma, Stage III, Cutaneous Melanoma by AJCC V7 Stage, Cutaneous Melanoma, Stage IV
Tested
Blood Sample, Health Related Quality of Life Questionnaires (HRQoL), Medical Chart Review
Sponsor
University of California, San Francisco

Who can join

Age
18 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 8

  • Minimum age: 18 years
  • Study condition: Cutaneous Melanoma, Cutaneous Melanoma, Stage III, Cutaneous Melanoma by AJCC V7 Stage, Cutaneous Melanoma, Stage IV
  • Adults ≥18 years of age
  • Able to speak and read English
  • Diagnosed with stage IIB, III, or IV cutaneous melanoma
  • Participants who are scheduled to receive \>=1 immune checkpoint inhibitor at University of California San Francisco medical center locations. Participants on targeted therapies (e.g., BRAF or mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors) will be eligible.
  • Provide written informed consent to participate in this study.
  • Participants with stage IIB or higher cutaneous melanoma

Exclusion 1

  • Participants will be excluded if they are unable to complete study requirements.

Where

1 site, 1 recruiting

University of California, San Francisco

San Francisco, California, United States

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.